| 國立成功大學 |
2023 |
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study
|
Chiu, Chiu C.-H.;Lin, M.-C.;Wei, Y.-F.;Chang, G.-C.;Su, W.-C.;Hsia, T.-C.;Su, J.;Wang, A.K.-F.;Jen, M.-H.;Puri, T.;Shih, J.-Y. |
| 臺大學術典藏 |
2021-04-23T05:56:33Z |
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis
|
Chih-Hsin Yang;Cheng Y.;Murakami H.;Yang P.-C.;He J.;Nakagawa K.;Kang J.H.;Kim J.-H.;Hozak R.R.;Nguyen T.S.;Zhang W.L.;Enatsu S.;Puri T.;Orlando M.; CHIH-HSIN YANG; Cheng Y.; Murakami H.; Yang P.-C.; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Hozak R.R.; Nguyen T.S.; Zhang W.L.; Enatsu S.; Puri T.; Orlando M. |
| 臺大學術典藏 |
2020-12-02T02:33:19Z |
Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations
|
Cheng Y.; Murakami H.; Pan-Chyr Yang; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Wang X.; Enatsu S.; Puri T.; Orlando M.; Yang J.C.-H.; Cheng Y.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-12-02T02:33:06Z |
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis
|
Yang J.C.-H.; PAN-CHYR YANG et al.; Yang J.C.-H.; Cheng Y.; Murakami H.; Pan-Chyr Yang; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Hozak R.R.; Nguyen T.S.; Zhang W.L.; Enatsu S.; Puri T.; Orlando M. |
| 臺大學術典藏 |
2020-08-13T06:33:40Z |
East Asian subgroup analysis of a randomized, double-blind, phase 3 study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small cell lung cancer following disease progression after one prior platinum-based therapy (REVEL)
|
Orlando M.; Puri T.; Alexandris E.; Lee P.; Zimmermann A.H.; Cho E.K.; Kang J.-H.; JIN-YUAN SHIH; Kim J.-H.; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:49Z |
First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results from a Randomized Phase III Trial
|
Chih-Hsin Yang;Rajan N;Kim J.S;Puri T;Orlando M;Tsai C.-M;Kang J.H;Srimuninnimit V;Wang X;Boye M; Boye M; Wang X; Srimuninnimit V; Kang J.H; Tsai C.-M; Orlando M; Puri T; Kim J.S; Rajan N; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:49Z |
First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results from a Randomized Phase III Trial
|
Chih-Hsin Yang;Rajan N;Kim J.S;Puri T;Orlando M;Tsai C.-M;Kang J.H;Srimuninnimit V;Wang X;Boye M; Boye M; Wang X; Srimuninnimit V; Kang J.H; Tsai C.-M; Orlando M; Puri T; Kim J.S; Rajan N; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Park K.;Wang X;Puri T;Orlando M;Mok T;Tsai C.-M;Kim S.-W;Lin C.-C;Ahn M.-J;Srimuninnimit V;Chih-Hsin Yang; CHIH-HSIN YANG; Srimuninnimit V; Ahn M.-J; Lin C.-C; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Park K.;Wang X;Puri T;Orlando M;Mok T;Tsai C.-M;Kim S.-W;Lin C.-C;Ahn M.-J;Srimuninnimit V;Chih-Hsin Yang; CHIH-HSIN YANG; Srimuninnimit V; Ahn M.-J; Lin C.-C; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:44Z |
Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations
|
Chih-Hsin Yang;Orlando M;Puri T;Enatsu S;Wang X;Kim J.-H;Kang J.H;Nakagawa K;He J;Yang P.-C;Murakami H;Cheng Y; Cheng Y; Murakami H; Yang P.-C; He J; Nakagawa K; Kang J.H; Kim J.-H; Wang X; Enatsu S; Puri T; Orlando M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:44Z |
Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations
|
Chih-Hsin Yang;Orlando M;Puri T;Enatsu S;Wang X;Kim J.-H;Kang J.H;Nakagawa K;He J;Yang P.-C;Murakami H;Cheng Y; Cheng Y; Murakami H; Yang P.-C; He J; Nakagawa K; Kang J.H; Kim J.-H; Wang X; Enatsu S; Puri T; Orlando M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:39Z |
Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al
|
Chih-Hsin Yang;Puri T;Orlando M;Cheng Y.; CHIH-HSIN YANG; Puri T; Orlando M; Cheng Y. |
| 臺大學術典藏 |
2020-05-26T09:26:39Z |
Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al
|
Chih-Hsin Yang;Puri T;Orlando M;Cheng Y.; CHIH-HSIN YANG; Puri T; Orlando M; Cheng Y. |
| 臺大學術典藏 |
2020-05-26T09:26:33Z |
A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non?�Small-Cell Lung Cancer
|
Park K.;Puri T;Orlando M;Han B;Mok T;Chih-Hsin Yang; CHIH-HSIN YANG; Mok T; Han B; Orlando M; Puri T; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:33Z |
A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non?�Small-Cell Lung Cancer
|
Park K.;Puri T;Orlando M;Han B;Mok T;Chih-Hsin Yang; CHIH-HSIN YANG; Mok T; Han B; Orlando M; Puri T; Park K. |
| 臺大學術典藏 |
2020-05-25T07:35:18Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Wang X; Park K.; Yang J.C.-H; Srimuninnimit V; Ahn M.-J; Chia-Chi Lin; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T |
| 臺大學術典藏 |
2020-05-25T02:45:31Z |
An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non�Vsmall cell lung cancer
|
Wang L; Wu Y.-L; Lu S; Deng L; Ahn M.-J; Feng-Ming Hsu; Iscoe N; Hossain A; Puri T; Zhang P; Orlando M. |
